Alpha-2-adrenergic and opioid receptor additivity in rat locus coeruleus neurons.
Functional interactions between G protein-coupled receptors (GPCRs) are widely reported whereas the mechanisms underlying these interactions remain unclear. A rapidly growing literature suggests that many GPCRs form heteromeric complexes and that these complexes may possess pharmacological and functional properties that differ from their respective parent receptors. In order to investigate the functional relationship between co-localized GPCRs in intact, native CNS neurons, we used intracellular recording techniques in locus coeruleus (LC) slices. The LC consists of a homogenous population of cells, all of which co-express micro-opioid and alpha(2A)-adrenergic receptors (microOR and alpha(2A)ARs, respectively). Co-administration of microOR and alpha(2A)AR agonists in vivo results in synergistic interactions in analgesic assays and heteromeric microOR-alpha(2A)AR complexes have been detected in HEK-293 co-expressing the two receptors. The LC is therefore an excellent model system to explore these interactions. Dose-response and isobolographic analysis of agonist-induced hyperpolarization in individual LC neurons revealed that the interaction between these receptors was not synergistic but additive. This result suggests that co-localized microOR and alpha(2)ARs are either not physically associated in these neurons or that heteromer formation may not fully explain the microOR-alpha(2A)AR synergistic interactions reported following agonist administration in vivo.
Stone
Laura S
LS
Department of Neuroscience, University of Minnesota, 6-145 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, USA. stone@med.umn.edu
Wilcox
George L
GL
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D066298:In Vitro Techniques; D008125:Locus Coeruleus / Q000187:drug effects / Q000378:metabolism*; D009294:Narcotics / Q000494:pharmacology; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects / Q000378:metabolism*; D043562:Receptors, G-Protein-Coupled / Q000187:drug effects / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000187:drug effects / Q000378:metabolism*
D000316:Adrenergic alpha-Agonists; D009294:Narcotics; D018341:Receptors, Adrenergic, alpha-2; D043562:Receptors, G-Protein-Coupled; D017450:Receptors, Opioid, mu